Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Debt / NOTE 4.000% 2/0
-
Market price (% of par)
-
97.46%
-
Total 13F principal
-
$113,836,013
-
Principal change
-
-$84,735,452
-
Total reported market value
-
$111,037,013
-
Number of holders
-
20
-
Value change
-
-$97,347,183
-
Number of buys
-
7
-
Number of sells
-
15
Institutional Holders of PDL BIOPHARMA INC - NOTE 4.000% 2/0 as of Q4 2016
As of 31 Dec 2016,
PDL BIOPHARMA INC - NOTE 4.000% 2/0 was held by
20 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$113,836,013
in principal (par value) of the bond.
The largest 10 bondholders included
ASCEND CAPITAL, LLC, UBS ASSET MANAGEMENT AMERICAS INC, WOLVERINE ASSET MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP, CNH PARTNERS LLC, Bank of New York Mellon Corp, WESTWOOD HOLDINGS GROUP INC, ZAZOVE ASSOCIATES LLC, CITADEL ADVISORS LLC, and MORGAN STANLEY.
This page lists
20
institutional bondholders reporting positions
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.